Pay in 4 interest-free payments of $6.84 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
In large RCTs, patients receiving semaglutide, 2.4 mg, lost a mean of 6% of their weight by week 12 and 12% of their weight by week 28
The STEP 1 trial, published in the New England Journal of Medicine, studied once-weekly semaglutide at 2.4mg in adults with overweight or obesity alongside lifestyle intervention
Tirzepatide may be appropriate for adults who: Have a BMI of 30 or higher Have a BMI of 27 or higher with weight-related health concerns Experience insulin resistance Struggle with persistent hunger or cravings Have not achieved sustainable weight loss through lifestyle changes alone Before beginning treatment, we take the time to sit down with you for a comprehensive consultation
Neither approach is inherently safer
US$ 27.45
US$ 24.79
US$ 23.93
US$ 20.73
